Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Apr 15, 2023; 15(4): 677-688
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.677
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.677
Table 4 Relative dose intensity and dose modification of the adjuvant chemotherapy
| FL (n = 30) | FP (n = 22) | |
| Duration of treatment, weeks, median (range) | 24.1 (7.9-29.0) | 24.1 (7.7-29.6) |
| Cycles of drug administration, median (range) | 6 (2-6) | 6 (2-6) |
| Relative dose intensity, mean (range) | 0.83 (0.27-1.00) | 0.85 (0.33-1.00) |
| Received all cycles of chemotherapy, n (%) | 20 (66.7) | 16 (72.7) |
| Dose reduction or interruption, n (%) | 10 (33.3) | 10 (45.5) |
| Discontinued adjuvant chemotherapy, n (%) | 10 (33.3) | 6 (27.3) |
| Relapse | 5 (16.7) | 2 (9.0) |
| Intolerance | 5 (16.7) | 4 (18.3) |
- Citation: Park SJ, Shin K, Kim IH, Hong TH, Kim Y, Lee MA. Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma. World J Gastrointest Oncol 2023; 15(4): 677-688
- URL: https://www.wjgnet.com/1948-5204/full/v15/i4/677.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.677